The Federal Court of Appeal has dismissed Apotex's appeal of a judicial review decision of the Therapeutic Products Directorate, which required Apotex to submit additional information concerning products manufactured or tested in Apotex's facilities in India (for further details please see "Apotex's appeal in judicial review of decision seeking further information from India facilities dismissed").
The Federal Court of Appeal found that the Federal Court made no reviewable error in its conclusion that the Therapeutic Products Directorate's decision was not improperly motivated. On 22 February 2019 the Supreme Court dismissed Apotex's application for leave to appeal (docket 38336).
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.